Latest Amines Stories
Presentation on January 13, 2015 at 8:50 AM Pacific Time NEW YORK, Jan. 7, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc.
Presentation on January 13, 2015 at 11:00 AM Pacific Time. NEW YORK, Jan. 6, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc.
SAN DIEGO, Dec.
- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec.
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Novel Product Being Studied to Treat Neuropathic Pain. NEW YORK, Dec. 22, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc.
Harbor Village Florida comments on US doctors prescribing less painkillers. USA (PRWEB) December 16, 2014 According to HealthDay News in the article
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
DUBLIN, Dec. 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it is filing an emergency appeal to the U.S.
In-demand research report “Glyphsoate China Monthly Report 1411” worked out by Guangzhou CCM Information Science & Technology Co.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.